Role of tumour necrosis factor-alpha and other cytokines in ischemia-reperfusion-induced injury in the heart

Experimental and Clinical Cardiology

Volumn 10, Issue 4, 2005, Pages 213-222

  Saini, Harjot K ^a   Xu, Yan Jun ^a   Zhang, Ming ^a   Liu, Peter P ^b   Kirshenbaum, Lorrie A ^a   Dhalla, Naranjan S ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cardiac dysfunction; Cytokines; Interleukins; Ischemic heart disease; TNF

Indexed keywords

CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CYTOKINE PRODUCTION; HEART INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; PATHOPHYSIOLOGY; REPERFUSION INJURY;

EID: 30344454375     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (156)

1. Braunwald E, Kloner RA. Myocardial reperfusion: A double-edged sword? J Clin Invest 1985;76:1713-9.
2. Pierce GN, Czubryt MP. The contribution of ionic imbalance to ischemia/reperfusion-induced injury. J Mol Cell Cardiol 1995;27:53-63.
3. Piper HM, Garcia-Dorado D, Ovize M. A fresh took at reperfusion injury. Cardiovasc Res 1998;38:291-300.
4. Opie LH. Reperfusion injury and its pharmacologic modification. Circulation 1989;80:1049-62.
5. Bolli R, Marban E. Molecular and cellular mechanisms of myocardial stunning. Physiol Rev 1999;79:609-34.
6. Dhalla NS, Golfman L, Takeda S, Takeda N, Nagano M. Evidence for the role of oxidative stress in acute ischemic heart disease: A brief review. Can J Cardiol 1999;15:587-93.
7. Guillen I, Blanes M, Gomez-Lechon MJ, Castell JV. Cytokine signaling during myocardial infarction: Sequential appearance of IL-1 beta and IL-6. Am J Physiol 1995;269:R229-35.
8. Weisensee D, Bereiter-Hahn J, Schoeppe W, Low-Friedrich I. Effects of cytokines on the contractility of cultured cardiac myocytes. Int J Immunopharmacol 1993;15:581-7.
9. Hebert CA, Luscinskas FW, Kiely JM, et al. Endothelial and leukocyte forms of IL-8. Conversion by thrombin and interactions with neutrophils. J Immunol 1990;145:3033-40.
10. Bursten SL. Interaction of lipopolysaccharide with a mammalian lyso-phosphatidate acyltransferase (LPAAT) transfected into E coli, and effect of lisofylline on LPAAT transfected into mammalian cells. Prog Clin Biol Res 1998;397:345-56.
11. Chen H, Li D, Saldeen T, Mehta JL. TGF-beta 1 attenuates myocardial ischemia-reperfusion injury via inhibition of upregulation of MMP-1. Am J Physiol Heart Circ Physiol 2003;284:H1612-7.
12. Bellisarii FL, Gallina S, De Caterina R. Tumor necrosis factor-alpha and cardiovascular diseases. Ital Heart J 2001;2:408-17.
13. Dhote-Burger P, Vuilleminot A, Lecompte T, et al. Neutrophil degranulation related to the reperfusion of ischemic human heart during cardiopulmonary bypass. J Cardiovasc Pharmacol 1995;25(Suppl 2):S124-9.
14. Cavaillon JM. Cytokines and macrophages. Biomed Pharmacother 1994;48:445-53.
15. Herskowitz A, Choi S, Ansari AA, Wesselingh S. Cytokine mRNA expression in postischemic/reperfused myocardium. Am J Pathol 1995;146:419-28.
16. Marx N, Neumann FJ, Ott I, et al. Induction of cytokine expression in leukocytes in acute myocardial infarction. J Am Coll Cardiol 1997;30:165-70.
17. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res 1991;262:3-11.
18. Sack M. Tumor necrosis factor-alpha in cardiovascular biology and the potential role for anti-tumor necrosis factor-alpha therapy in heart disease. Pharmacol Ther 2002;94:123-35.
19. Torre-Amione G, Kapadia S, Lee J, Bies RD, Lebovitz R, Mann DL. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 1995;92:1487-93.
20. Celec P. Nuclear factor kappa B - molecular biomedicine: The next generation. Biomed Pharmacother 2004;58:365-71.
21. Meldrum DR. Tumor necrosis factor in the heart. Am J Physiol 1998;274:R577-95.
22. Meldrum DR, Cleveland JC Jr, Cain BS, Meng X, Harken AH. Increased myocardial tumor necrosis factor-alpha in a crystalloid-perfused model of cardiac ischemia-reperfusion injury. Ann Thorac Surg 1998;65:439-43.
23. Shames BD, Barton HH, Reznikov LL, et al. Ischemia alone is sufficient to induce TNF-alpha mRNA and peptide in the myocardium. Shock 2002;17:114-9.
24. Meldrum DR, Meng X, Dinarello CA, et al. Human myocardial tissue TNFalpha expression following acute global ischemia in vivo. J Mol Cell Cardiol 1998;30:1683-9.
25. Gurevitch J, Frolkis I, Yuhas Y, et al. Tumor necrosis factor-alpha is released from the isolated heart undergoing ischemia and reperfusion. J Am Coll Cardiol 1996;28:247-52.
26. Cain BS, Harken AH, Meldrum DR. Therapeutic strategies to reduce TNF-alpha mediated cardiac contractile depression following ischemia and reperfusion. J Mol Cell Cardiol 1999;31:931-47.
27. Bergman MR, Holycross BJ. Pharmacological modulation of myocardial tumor necrosis factor alpha production by phosphodiesterase inhibitors. J Pharmacol Exp Ther 1996;279:247-54. (Erratum in 1997;280:520).
28. Wagner DR, McTiernan C, Sanders VJ, Feldman AM. Adenosine inhibits lipopolysaccharide-induced secretion of tumor necrosis factor-alpha in the failing human heart. Circulation 1998;97:521-4.
29. Peng J, Xiao J, Ye F, Deng HW, Li YJ. Inhibition of cardiac tumor necrosis factor-alpha production by calcitonin gene-related peptide-mediated ischemic preconditioning in isolated rat hearts. Eur J Pharmacol 2000;407:303-8.
30. Meldrum DR, Dinarello CA, Shames BD, et al. Ischemic preconditioning decreases postischemic myocardial tumor necrosis factor-alpha production. Potential ultimate effector mechanism of preconditioning. Circulation 1998;98:II214-8.
31. Cain BS, Meldrum DR, Dinarello CA, Meng X, Banerjee A, Harken AH. Adenosine reduces cardiac TNF-alpha production and human myocardial injury following ischemia-reperfusion. J Surg Res 1998;76:117-23.
32. Cain BS, Meldrum DR, Meng X, et al. p38 MAPK inhibition decreases TNF-alpha production and enhances postischemic human myocardial function. J Surg Res 1999;83:7-12.
33. Gurevitch J, Frolkis I, Yuhas Y, et al. Anti-tumor necrosis factor-alpha improves myocardial recovery after ischemia and reperfusion. J Am Coll Cardiol 1997;30:1554-61.
34. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992;257:387-9.
35. Rathi SS, Xu YJ, Dhalla NS. Mechanism of cardioprotective action of TNF-α in the isolated rat heart. Exp Clin Cardiol 2002;7:146-50.
36. Thielmann M, Dorge H, Martin C, et al. Myocardial dysfunction with coronary microembolization: Signal transduction through a sequence of nitric oxide, tumor necrosis factor-alpha, and sphingosine. Circ Res 2002;90:807-13.
37. Cailleret M, Amadou A, Andrieu-Abadie N, et al. N-acetylcysteine prevents the deleterious effect of tumor necrosis factor-(alpha) on calcium transients and contraction in adult rat cardiomyocytes. Circulation 2004;109:406-11.
38. Oral H, Dorn GW II, Mann DL. Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian cardiac myocyte. J Biol Chem 1997;272:4836-42.
39. Mathias S, Dressler KA, Kolesnick RN. Characterization of a ceramide-activated protein kinase: Stimulation by tumor necrosis factor alpha. Proc Natl Acad Sci USA 1991;88:10009-13.
40. Dettbarn CA, Betto R, Salviati G, Palade P, Jenkins GM, Sabbadini RA. Modulation of cardiac sarcoplasmic reticulum ryanodine receptor by sphingosine. J Mol Cell Cardiol 1994;26:229-42.
41. i and contractility in isolated adult rabbit ventricular myocytes. Am J Physiol 1996;271:H1449-55.
42. Prabhu SD. Cytokine-induced modulation of cardiac function. Circ Res 2004;95:1140-53.
43. Schutze S, Machleidt T, Kronke M. Mechanisms of tumor necrosis factor action. Semin Oncol 1992;19(Suppl 4):16-24.
44. Park H, Park SG, Kim J, Ko YG, Kim S. Signaling pathways for TNF production induced by human aminoacyl-tRNA synthetase-associating factor, p43. Cytokine 2002;20:148-53.
45. Dhalla NS, Xu YJ, Sheu SS, Tappia PS, Panagia V. Phosphatidic acid: A potential signal transducer for cardiac hypertrophy. J Mol Cell Cardiol 1997;29:2865-71.
46. Cain BS, Meldrum DR, Harken AH. Protein kinase C in normal and pathologic myocardial states. J Surg Res 1999;81:249-59.
47. Schutze S, Potthoff K, Machleidt T, Berkovic D, Wiegmann K, Kronke M. TNF activates NF-kappa B by phosphatidylcholine-specific phospholipase C-induced "acidic" sphingomyelin breakdown. Cell 1992;71:765-76.
48. Plo I, Lautier D, Levade T, et al. Phosphatidylcholine-specific phospholipase C and phospholipase D are respectively implicated in mitogen-activated protein kinase and nuclear factor kappaB activation in tumour-necrosis-factor-alpha-treated immature acute-myeloid-leukaemia cells. Biochem J 2000;351:459-67.
49. 2 isoforms by TNF-alpha and IL-1beta in adult rat ventricular myocytes. Am J Physiol 1998;275:H1462-72.
50. Alessenko AV. Functions of sphingosine in cell proliferation and death. Biochemistry 1998;63:62-8.
51. Cleveland JL, Ihle JN. Contenders in FasL/TNF death signaling. Cell 1995;81:479-82.
52. McCarthy JV, Ni J, Dixit VM. RIP2 is a novel NF-kappaB-activating and cell death-inducing kinase. J Biol Chem 1998;273:16968-75.
53. van den Hoff MJ, van den Eijnde SM, Viragh S, Moorman AF. Programmed cell death in the developing heart. Cardiovasc Res 2000;45:603-20.
54. Natoli G, Costanzo A, Guido F, Moretti F, Levrero M. Apoptotic, non-apoptotic, and anti-apoptotic pathways of tumor necrosis factor signalling. Biochem Pharmacol 1998;56:915-20.
55. Perkins ND. Achieving transcriptional specificity with NF-kappa B. Int J Biochem Cell Biol 1997;29:1433-48.
56. Krown KA, Page MT, Nguyen C, et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 1996;98:2854-65.
57. Song W, Lu X, Feng Q. Tumor necrosis factor-alpha induces apoptosis via inducible nitric oxide synthase in neonatal mouse cardiomyocytes. Cardiovasc Res 2000;45:595-602.
58. Wan S, DeSmet JM, Barvais L, Goldstein M, Vincent JL, LeClerc JL. Myocardium is a major source of proinflammatory cytokines in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1996;112:806-11.
59. Hennein HA, Ebba H, Rodriguez JL, et al. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. J Thorac Cardiovasc Surg 1994;108:626-35.
60. Lantz M, Malik S, Slevin ML, Olsson I. Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine 1990;2:402-6.
61. Aderka D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev 1996;7:231-40.
62. Mullberg J, Durie FH, Otten-Evans C, et al. A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J Immunol 1995;155:5198-205.
63. Crowe PD, Walter BN, Mohler KM, Otten-Evans C, Black RA, Ware CF. A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J Exp Med 1995;181:1205-10.
64. Ferrari R. The role of TNF in cardiovascular disease. Pharmacol Res 1999;40:97-105.
65. Zhao TC, Taher MM, Valerie KC, Kukreja RC. p38 Triggers late preconditioning elicited by anisomycin in heart: Involvement of NF-kappaB and iNOS. Circ Res 2001;89:915-22.
66. van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF. Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. J Clin Invest 1996;97:713-9.
67. Maekawa N, Wada H, Kanda T, et al. Improved myocardial ischemia/reperfusion injury in mice lacking tumor necrosis factor-alpha. J Am Coll Cardiol 2002;39:1229-35.
68. Latini R, Bianchi M, Correale E, et al. Cytokines in acute myocardial infarction: Selective increase in circulating tumor necrosis factor, its soluble receptor, and interleukin-1 receptor antagonist. J Cardiovasc Pharmacol 1994;23:1-6.
69. Nelson SK, Wong GH, McCord JM. Leukemia inhibitory factor and tumor necrosis factor induce manganese superoxide dismutase and protect rabbit hearts from reperfusion injury. J Mol Cell Cardiol 1995;27:223-9.
70. Gershenwald JE, Fong YM, Fahey TJ III, et al. Interleukin 1 receptor blockade attenuates the host inflammatory response. Proc Natl Acad Sci USA 1990;87:4966-70.
71. Alexander HR, Wong GG, Doherty GM, Venzon DJ, Fraker DL, Norton JA. Differentiation factor/leukemia inhibitory factor protection against lethal endotoxemia in mice: Synergistic effect with interleukin 1 and tumor necrosis factor. J Exp Med 1992;175:1139-42.
72. Benigni F, Villa F, Demitri MT, et al. Ciliary neurotrophic factor inhibits brain and peripheral tumor necrosis factor production and, when coadministered with its soluble receptor, protects mice from lipopolysaccharide toxicity. Mol Med 1995;1:568-75.
73. McGeehan GM, Becherer JD, Bast RC Jr, et al. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature 1994;370:558-61.
74. Mohler KM, Sleath PR, Fitzner JN, et al. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 1994;370:218-20.
75. Hill GE, Springall DR, Robbins RA. Aprotinin is associated with a decrease in nitric oxide production during cardiopulmonary bypass. Surgery 1997;121:449-55.
76. Nakano M, Mann DL, Knowlton AA. Blocking the endogenous increase in HSP 72 increases susceptibility to hypoxia and reoxygenation in isolated adult feline cardiocytes. Circulation 1997;95:1523-31.
77. Feinstein DL, Galea E, Aquino DA, Li GC, Xu H, Reis DJ. Heat shock protein 70 suppresses astroglial-inducible nitric-oxide synthase expression by decreasing NFkappaB activation. J Biol Chem 1996;271:17724-32.
78. Plumier JC, Ross BM, Currie RW, et al. Transgenic mice expressing the human heat shock protein 70 have improved post-ischemic myocardial recovery. J Clin Invest 1995;95:1854-60.
79. Sumeray MS, Rees DD, Yellon DM. Infarct size and nitric oxide synthase in murine myocardium. J Mol Cell Cardiol 2000;32:35-42.
80. Smith RM, Suleman N, McCarthy J, Sack MN. Classic ischemic but not pharmacologic preconditioning is abrogated following genetic ablation of the TNFalpha gene. Cardiovasc Res 2002;55:553-60.
81. Lecour S, Smith RM, Woodward B, Opie LH, Rochette L, Sack MN. Identification of a novel role for sphingolipid signaling in TNF alpha and ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol 2002;34:509-18.
82. 2+ transients and contraction of adult rat cardiomyocytes. Am J Physiol Cell Physiol 2002;282:C1339-47.
83. Bowie A, O'Neill LA. Oxidative stress and nuclear factor-kappaB activation: A reassessment of the evidence in the light of recent discoveries. Biochem Pharmacol 2000;59:13-23.
84. Valen G, Yan ZQ, Hansson GK. Nuclear factor kappa-B and the heart. J Am Coll Cardiol 2001;38:307-14.
85. Mann DL. Stress activated cytokines and the heart. Cytokine Growth Factor Rev 1996;7:341-54.
86. Li C, Browder W, Kao RL. Early activation of transcription factor NF-kappaB during ischemia in perfused rat heart. Am J Physiol 1999;276:H543-52.
87. Chandrasekar B, Freeman GL. Induction of nuclear factor kappaB and activation protein 1 in postischemic myocardium. FEBS Lett 1997;401:30-4.
88. Shimizu, N, Yoshiyama M, Omura T, et al. Activation of mitogen-activated protein kinases and activator protein-1 in myocardial infarction in rats. Cardiovasc Res 1998;38:116-24.
89. Fan H, Sun B, Gu Q, Lafond-Walker A, Cao S, Becker LC. Oxygen radicals trigger activation of NF-kappaB and AP-1 and upregulation of ICAM-1 in reperfused canine heart. Am J Physiol Heart Circ Physiol 2002;282:H1778-86.
90. Yang J, Maiden JJ, Fan C, et al. Genetic redox preconditioning differentially modulates AP-1 and NFkappaB responses following cardiac ischemia/reperfusion injury and protects against necrosis and apoptosis. Mol Ther 2003;7:341-53.
91. 2+ response amplitude and duration. Nature 1997;386:855-8. (Erratum in 1997;388:308).
92. Dolmetsch RE, Xu K, Lewis RS. Calcium oscillations increase the efficiency and specificity of gene expression. Nature 1998;392:933-6.
93. i oscillation frequency regulates agonist-stimulated NF-kappaB transcriptional activity. J Biol Chem 1999;274:33995-8.
94. Cargnoni A, Ceconi C, Gaia G, Agnoletti L, Ferrari R. Cellular thiols redox status: A switch for NF-kappaB activation during myocardial post-ischaemic reperfusion. J Mol Cell Cardiol 2002;34:997-1005.
95. Suzuki YJ, Packer L. Inhibition of NF-kappa B DNA binding activity by alpha-tocopheryl succinate. Biochem Mol Biol Int 1993;31:693-700.
96. Suzuki YJ, Aggarwal BB, Packer L. Alpha-lipoic acid is a potent inhibitor of NF-kappa B activation in human T cells. Biochem Biophys Res Commun 1992;189:1709-15.
97. Pye J, Ardeshirpour F, McCain A, et al. Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury. Am J Physiol Heart Circ Physiol 2003;284:H919-26.
98. Bretschneider E, Wittpoth M, Weber AA, Glusa E, Schror K. Activation of NFkappaB is essential but not sufficient to stimulate mitogenesis of vascular smooth muscle cells. Biochem Biophys Res Commun 1997;235:365-8.
99. Bellas RE, Lee JS, Sonenshein GE. Expression of a constitutive NF-kappa B-like activity is essential for proliferation of cultured bovine vascular smooth muscle cells. J Clin Invest 1995;96:2521-7.
100. Thourani VH, Brar SS, Kennedy TP, et al. Nonanticoagulant heparin inhibits NF-kappaB activation and attenuates myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 2000;278:H2084-93.
101. Xuan YT, Tang XL, Banerjee S, et al. Nuclear factor-kappaB plays an essential role in the late phase of ischemic preconditioning in conscious rabbits. Circ Res 1999;84:1095-109.
102. Maulik N, Sato M, Price BD, Das DK. An essential role of NFkappaB in tyrosine kinase signaling of p38 MAP kinase regulation of myocardial adaptation to ischemia. FEBS Lett 1998;429:365-9.
103. Marber MS, Latchman DS, Walker JM, Yellon DM. Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation 1993;88:1264-72.
104. 1 receptors: Evidence from gene-knockout mice. Circulation 2000;102:902-7.
105. Morgan EN, Boyle EM Jr, Yun W, et al. An essential role for NF-kappaB in the cardioadaptive response to ischemia. Ann Thorac Surg 1999;68:377-82.
106. Bach FH, Hancock WW, Ferran C. Protective genes expressed in endothelial cells: A regulatory response to injury. Immunol Today 1997;18:483-6.
107. Regula KM, Ens K, Kirshenbaum LA. IKK beta is required for Bcl-2-mediated NF-kappa B activation in ventricular myocytes. J Biol Chem 2002;277:38676-82.
108. Mustapha S, Kirshner A, De Moissac D, Kirshenbaum LA. A direct requirement of nuclear factor-kappa B for suppression of apoptosis in ventricular myocytes. Am J Physiol Heart Circ Physiol 2000;279:H939-45.
109. Regula KM, Baetz D, Kirshenbaum LA. Nuclear factor-kappaB represses hypoxia-induced mitochondrial defects and cell death of ventricular myocytes. Circulation 2004;110:3795-802.
110. Roberts AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta). Growth Factors 1993;8:1-9.
111. Mehta JL, Yang BC, Strates BS, Mehta P. Role of TGF-beta1 in platelet-mediated cardioprotection during ischemia-reperfusion in isolated rat hearts. Growth Factors 1999;16:179-90.
112. Yellon DM, Baxter GF. Reperfusion injury revisited: Is there a role for growth factor signaling in limiting lethal reperfusion injury? Trends Cardiovasc Med 1999;9:245-9.
113. Lefer AM, Tsao P, Aoki N, Palladino MA Jr. Mediation of cardioprotection by transforming growth factor-beta. Science 1990;249:61-4.
114. Lefer AM, Ma XL, Weyrich AS, Scalia R. Mechanism of the cardioprotective effect of transforming growth factor beta 1 in feline myocardial ischemia and reperfusion. Proc Natl Acad Sci USA 1993;90:1018-22.
115. Baxter GF, Mocanu MM, Brar BK, Latchman DS, Yellon DM. Cardioprotective effects of transforming growth factor-beta1 during early reoxygenation or reperfusion are mediated by p42/p44 MAPK. J Cardiovasc Pharmacol 2001;38:930-9.
116. Grunenfelder J, Miniati DN, Murata S, Falk V, Hoyt EG, Robbins RC. Up-regulation of Bcl-2 through hyperbaric pressure transfection of TGF-beta1 ameliorates ischemia-reperfusion injury in rat cardiac allografts. J Heart Lung Transplant 2002;21:244-50.
117. Mehta JL, Chen HJ, Li DY. Protection of myocytes from hypoxia-reoxygenation injury by nitric oxide is mediated by modulation of transforming growth factor-beta1. Circulation 2002;105:2206-11.
118. Chen H, Li D, Saldeen T, Mehta JL. TGF-beta1 modulates NOS expression and phosphorylation of Akt/PKB in rat myocytes exposed to hypoxia-reoxygenation. Am J Physiol Heart Circ Physiol 2001;281:H1035-9.
119. Evans HG, Lewis MJ, Shah AM. Interleukin-1 beta modulates myocardial contraction via dexamethasone sensitive production of nitric oxide. Cardiovasc Res 1993;27:1486-90.
120. Oyama J, Shimokawa H, Momii H, et al. Role of nitric oxide and peroxynitrite in the cytokine-induced sustained myocardial dysfunction in dogs in vivo. J Clin Invest 1998;101:2207-14.
121. Stangl V, Baumann G, Stangl K, Felix SB. Negative inotropic mediators released from the heart after myocardial ischaemia-reperfusion. Cardiovasc Res 2002;53:12-30.
122. LaPointe MC, Isenovic E. Interleukin-1beta regulation of inducible nitric oxide synthase and cyclooxygenase-2 involves the p42/44 and p38 MAPK signaling pathways in cardiac myocytes. Hypertension 1999;33:276-82.
123. 2+-independent nitric oxide synthase in the myocardium. Br J Pharmacol 1992;105:575-80.
124. Pinsky DJ, Cai B, Yang X, Rodriguez C, Sciacca RR, Cannon PJ. The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor beta. J Clin Invest 1995;95:677-85.
125. Brown JM, White CW, Terada LS, et al. Interleukin 1 pretreatment decreases ischemia/reperfusion injury. Proc Natl Acad Sci USA 1990;87:5026-30.
126. Thaik CM, Calderone A, Takahashi N, Colucci WS. Interleukin-1 beta modulates the growth and phenotype of neonatal rat cardiac myocytes. J Clin Invest 1995;96:1093-9.
127. McTiernan CF, Lemster BH, Frye C, Brooks S, Combes A, Feldman AM. Interleukin-1 beta inhibits phospholamban gene expression in cultured cardiomyocytes. Circ Res 1997;81:493-503.
128. Maulik N, Engelman RM, Wei Z, Lu D, Rousou JA, Das DK. Interleukin-1 alpha preconditioning reduces myocardial ischemia reperfusion injury. Circulation 1993;88:II387-94.
129. Nogae C, Makino N, Hata T, et al. Interleukin 1 alpha-induced expression of manganous superoxide dismutase reduces myocardial reperfusion injury in the rat. J Mol Cell Cardiol 1995;27:2091-9.
130. Wollert KC, Drexler H. The role of interleukin-6 in the failing heart. Heart Fail Rev 2001;6:95-103.
131. Miyao Y, Yasue H, Ogawa H, et al. Elevated plasma interleukin-6 levels in patients with acute myocardial infarction. Am Heart J 1993;126:1299-304.
132. Chandrasekar B, Mitchell DH, Colston JT, Freeman GL. Regulation of CCAAT/Enhancer binding protein, interleukin-6, interleukin-6 receptor, and gp130 expression during myocardial ischemia/reperfusion. Circulation 1999;99:427-33.
133. Gwechenberger M, Mendoza LH, Youker KA, et al. Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation 1999;99:546-51.
134. Kukielka GL, Youker KA, Michael LH, et al. Role of early reperfusion in the induction of adhesion molecules and cytokines in previously ischemic myocardium. Mol Cell Biochem 1995;147:5-12.
135. Finkel MS, Hoffman RA, Shen L, Oddis CV, Simmons RL, Hattler BG. Interleukin-6 (IL-6) as a mediator of stunned myocardium. Am J Cardiol 1993;71:1231-2.
136. i and cell contraction in cultured chick ventricular myocytes. Circ Res 1994;75:285-95.
137. Kukielka GL, Smith CW, Manning AM, Youker KA, Michael LH, Entman ML. Induction of interleukin-6 synthesis in the myocardium. Potential role in postreperfusion inflammatory injury. Circulation 1995;92:1866-75.
138. Stephanou A, Brar B, Heads R, et al. Cardiotrophin-1 induces heat shock protein accumulation in cultured cardiac cells and protects them from stressful stimuli. J Mol Cell Cardiol 1998;30:849-55.
139. Latchman DS. Cardiotrophin-1 (CT-1): A novel hypertrophic and cardioprotective agent. Int J Exp Pathol 1999;80:189-96.
140. Craig R, Larkin A, Mingo AM, et al. p38 MAPK and NF-kappa B collaborate to induce interleukin-6 gene expression and release. Evidence for a cytoprotective autocrine signaling pathway in a cardiac myocyte model system. J Biol Chem 2000;275:23814-24.
141. Kukielka GL, Smith CW, LaRosa GJ, et al. Interleukin-8 gene induction in the myocardium after ischemia and reperfusion in vivo. J Clin Invest 1995;95:89-103.
142. Dame JB, Juul SE. The distribution of receptors for the pro-inflammatory cytokines interleukin (IL)-6 and IL-8 in the developing human fetus. Early Hum Dev 2000;58:25-39.
143. Oz MC, Liao H, Naka Y, et al. Ischemia-induced interleukin-8 release after human heart transplantation. A potential role for endothelial cells. Circulation 1995;92:II428-32.
144. Abe Y, Kawakami M, Kuroki M, et al. Transient rise in serum interleukin-8 concentration during acute myocardial infarction. Br Heart J 1993;70:132-4.
145. Huber AR, Kunkel SL, Todd RF III, Weiss SJ. Regulation of transendothelial neutrophil migration by endogenous interleukin-8. Science 1991;254:99-102. (Erratum in 1991;254:631).
146. Boyle EM Jr, Kovacich JC, Hebert CA, et al. Inhibition of interleukin-8 blocks myocardial ischemia-reperfusion injury. J Thorac Cardiovasc Surg 1998;116:114-21.
147. Moser R, Olgiati L, Patarroyo M, Fehr J. Chemotaxins inhibit neutrophil adherence to and transmigration across cytokine-activated endothelium: Correlation to the expression of L-selectin. Eur J Immunol 1993;23:1481-7.
148. Luscinskas FW, Kiely JM, Ding H, et al. In vitro inhibitory effect of IL-8 and other chemoattractants on neutrophil-endothelial adhesive interactions. J Immunol 1992;149:2163-71.
149. Lee LF, Louie MC, Desai SJ, et al. Interleukin-8 confers androgen-independent growth and migration of LNCaP: Differential effects of tyrosine kinases Src and FAK. Oncogene 2004;23:2197-205.
150. Smart SJ, Casale TB. TNF-alpha-induced transendothelial neutrophil migration is IL-8 dependent. Am J Physiol 1994;266:L238-45.
151. Smith WB, Gamble JR, Clark-Lewis I, Vadas MA. Interleukin-8 induces neutrophil transendothelial migration. Immunology 1991;72:65-72.
152. Neumann FJ, Ott I, Gawaz M, et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation 1995;92:748-55.
153. Irwin MW, Mak S, Mann DL, et al. Tissue expression and immunolocalization of tumor necrosis factor-alpha in postinfarction dysfunctional myocardium. Circulation 1999;99:1492-8.
154. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 2004;94:1543-53.
155. 2+-overload. Biochem Biophys Res Commun 2005; 327:57-63.
156. Zhang M, Xu YJ, Saini HK, Turan B, Liu PP, Dhalla NS. Pentoxifylline attenuates cardiac dysfunction and reduces TNF-alpha level in ischemic-reperfused heart. Am J Physiol Heart Circ Physiol 2005;289:H832-9.